The public markets for biotech have been volatile in recent months, causing concern that sustained instability could have a trickle-down effect to private investment in the biopharma space. Investors speaking on a panel at the BIO CEO & Investor Conference on 14 February said they anticipate more headwinds when it comes to private fundraising, but that substantial cash remains available for the right companies and business theses.
"There is a lot of private capital out there, so on the one hand, there is plenty of capital," Avoro Ventures partner Sara Nayeem said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
